The role of endothelin-1 (ET-1) in the kidney has been under study for many years; however, the complex mechanisms by which endothelin controls the physiology/pathophysiology of this organ are not fully resolved. This review aims to summarize recent findings in the field, especially regarding glomerular and tubular damage, Na þ /water homeostasis and sex differences in ET-1 function.
INTRODUCTION
Endothelin-1 (ET-1) is a 21 amino acid peptide that has been described as the most potent vasoconstrictor in the human body. ET-1 is produced by almost every cell type in the kidney. However, evidence demonstrates that most of the production is by endothelial and tubular cells, primarily principal cells of the inner medullary collecting duct. There is a similar distribution of ET A receptors (ET A Rs) and ET B receptors (ET B Rs) that suggest an autocrine function. Overactivation and dysfunction of the renal ET-1 system leads to renal disease that seems to result from an imbalance of ET A R over ET B R activity. The purpose of this mini review is to examine the role of the endothelin system in the kidney, with a focus on the most recent evidence on the mechanisms involved.
ENDOTHELIN-1 EFFECTS ON THE GLOMERULAR FILTRATION BARRIER
The glomerular capillary wall consists of three principal interdependent components: an internal layer of endothelial cells, a middle acellular layer of glomerular basement membrane, and an external layer of epithelial cells called podocytes. The properties and functions of this complex barrier can be modified by the ET-1 system [1] [2] [3] [4] , as summarized in Fig. 1 . We will focus on the effects of ET-1 on the podocytes, highlighting recent findings on the involvement of ET-1 in podocyte/glomerular impairment and emphasizing promising therapeutic targets.
Podocytes, with their complex cytoarchitecture and interdigitated foot process, are critical determinants of the integrity of the glomerular filtration barrier, and their injury leads to proteinuria, glomerulosclerosis, and progression of renal disease [5] . Moreover, podocytes produce, secrete, and bind ET-1 [6] , thus appearing to function as an autocrine target for this potent peptide [7] . Endothelial cells are considered a principal source of ET-1 within the glomeruli [8] . However, new data underline the importance of endothelium-podocyte crosstalk as a major determinant of a healthy filtration barrier [9] and so the cellular location of ET-1 production and function in renal disease is not clear. Autocrine and paracrine ET-1 signaling is considered to be crucial in contributing toward the development of albuminuria [10] . Podocytes produce vascular endothelial growth factor (VEGF), which acts on podocytes and neighboring endothelial cells and maintains the health of the endothelium [11] . Loss of VEGF function leads to endothelial dysfunction and proteinuria. Most importantly, loss of VEGF promotes actin cytoskeleton disruption and podocyte impairment by promoting ET-1 release, thereby resulting in severe proteinuria [12] . Moreover, a soluble form of VEGF receptor 1 (soluble fmslike tyrosine kinase 1) binds podocyte-derived VEGF and neutralizes its effects on endothelial cells, leading to endothelial damage and proteinuria [13] . Soluble fms-like tyrosine kinase 1 also binds to lipid microdomains in podocytes producing structural and functional changes in podocytes and glomerular filtration barrier [12] . On the other hand, increased levels of b-arrestin-1 can activate podocyte motility and sustain glomerular injury. ET-1, via upregulated ET A R, promotes ET A R/b-arrestin-1/ Src kinase complex formation, leading to epidermal growth factor receptor transactivation, b-catenin phosphorylation, and increased Snail expression, resulting in podocyte dysfunction and depletion. ET A R blockade prevented podocyte loss and lesion formation, as well as normalized b-arrestin-1 and Snail, suggesting ET A R antagonism as a potential therapeutic approach in progressive glomerulopathies [14 && ]. Moreover, recent studies suggest that ET A R antagonism may partially restore podocyte impairment and prevent podocyte loss [15, 16] ; however, the underlying mechanism remains unclear.
ET-1 has also been implicated in numerous pathophysiological mechanisms within the glomeruli contributing to podocyturia and proteinuria in multiple forms of chronic kidney disease, such as diabetic nephropathy [17] , sickle nephropathy [18] , hypertensive nephropathy [16] , or focal segmental glomerulosclerosis [6] . Blockade of endothelin receptors protects or delays ET-1 effects in these proteinuric renal diseases, highlighting the therapeutic efficacy of ET-1 antagonists and the importance of further preclinical and clinical studies.
ENDOTHELIN AND RENAL TUBULAR DAMAGE: NEW PERSPECTIVES
The involvement of ET-1 in the development of renal injury is well documented in the literature.
KEY POINTS
ET-1 leads to podocyte damage by promoting actin cytoskeleton disruption via ET A R activation in these cells.
Vascular ET-1 induces tubular ER stress and apoptosis in a paracrine manner.
In response to high salt intake, high tubular flow activates ET A R in IMCD to increase ENaC-dependent nitric oxide production.
ET B R is renoprotective in women, not men; however, more research in the sex dimorphism in the renal ET-1 system will ensure better therapies. Despite many of these reports being centered on the role of this peptide in glomerular diseases, all the components of the ET-1 system are also present in renal tubular cells and their expression is exaggerated during renal injury. Accordingly, several reports document that ET-1 also participates in tubulointerstitial renal disease, as recently reviewed [19] . Human studies using antagonists of ET A R and studies using transgenic animal models showed that the ET-1 system is involved in renal tubular injury associated with ischemia-reperfusion [20] and with radiocontrast-induced or sepsis-induced acute kidney injury (AKI) [21] . Other evidence also indicates the involvement of ET-1 in the formation of tubular cysts during polycystic kidney disease [19] .
Despite many studies linking ET-1 and renal tubular damage, the exact molecular mechanisms by which ET-1 contributes to the pathogenesis of renal disease remain unknown. In recent years, reports have highlighted the induction of endoplasmic reticulum (ER) stress as a possible mechanism promoting ET-1-induced renal apoptosis and renal injury. ER stress is a type of cellular stress caused by accumulation of unfolded proteins in the ER. The cell responds by activating the adaptive unfolded protein response that aims to restore cellular homeostasis by decreasing further protein transcription and translation, and by increasing expression of ER chaperones to fold the accumulated proteins. However, prolonged or severe upregulation of this pathway eventually leads to cell death and organ damage. There is accumulating evidence of a pathophysiological role of ER stress in acute and chronic kidney disease [22 && ]. Interestingly, both ET-1 and ER stress are upregulated in renal tubules in, among other renal diseases, contrast-induced AKI [23, 24] , ischemia-reperfusion injury [25, 20] , septic shockinduced AKI [26, 27] , or diabetic nephropathy [28, 29] , suggesting that overactivation of the ET-1 system leads to induction of the ER stress response in renal tubular cells. Further, a very recent report also links stimulation of ER stress pathways in renal proximal cells with the activation of the nod-like receptor containing pyrin domain 3 (NLRP3) inflammasome, a key inducer of tubulointerstitial inflammation, a hallmark of renal injury [30 & ].
Interesting studies performed by Arfian et al. [31] also highlight the importance of ET-1 originating from the vascular endothelium in causing proximal tubular damage during ischemia-reperfusion injury. Using a model of mouse lacking ET-1, specifically in vascular endothelial cells (vascular endothelial cell ET-1 knockout mice), these investigators demonstrated that the lack of endothelium-derived ET-1 not only attenuated proximal tubular injury in response to ischemia-reperfusion but also decreased inflammatory and oxidative stress responses. These results suggest that ET-1 produced by the vascular endothelium acts in a paracrine manner on neighboring epithelial cells to induce renal injury [32] . Results from our own laboratory support these observations. Using vascular endothelial cell ET-1 knockout mice, we observed that endothelial ET-1 is critical for the development of outer medullary tubular apoptosis in response to acute treatment with the AKI-inducer tunicamycin [33] and that ET A R blockade diminishes tunicamycin-induced tubular apoptosis in the ET B R deficient rat [34] .
All this evidence supports a critical role for ET-1 in the initiation of renal tubular injury (Fig. 2) and highlights the ET-1 system as a target against the development of tubular ER stress, apoptosis, and renal disease.
RENAL ENDOTHELIN AND SODIUM/ WATER HOMEOSTASIS: RECENT FINDINGS
The physiological role of ET-1 is to inhibit Na þ and water reabsorption by the nephron, which is especially important as salt intake is increased [35] . Release of ET-1, mainly by principal cells of the inner medullary collecting duct, is thought to occur in response to increased tubular flow and shear stress, and possibly to increased osmolality associated with high salt intake [36] [37] [38] [39] [40] . Until recently, it was thought that inhibition of Na þ reabsorption was primarily through activation of type B receptors (ET B R); however, recent findings suggest an integral role of ET A R. Recent reviews discussed mechanisms by which ET-1 regulates Na þ balance by each portion of the nephron [35, 41] , therefore, we will only focus on new findings related to mechanisms of ET-1 release and the potential 'hidden' role of tubular ET A R.
Increased salt intake induces renal tubular production of ET-1, which, in turn, inhibits epithelial Na þ channels (ENaC) to reduced tubular reabsorption and contributes to natriuresis [41] . Recently, Pandit et al. [39] demonstrated that increased shear stress significantly increases ET-1 production by mouse inner medullary collecting duct cells 3 (mIMCD3) through polycystin-2 and intracellular Ca 2þ spikes. Interestingly, blockade of ENaC did not affect flow-mediated increases in ET-1 [40] . However, a recent study [42 && ] suggests that higher flow rates (three to 10-fold higher than Pandit et al.) increase nitric oxide production by mIMCD3 cells, a response that is dependent on activation of ET B R. Further, benzamil, an ENaC blocker, prevents the nitric oxide increase in response to shear stress, suggesting an ENaCdependent mechanism [42 && ]. In addition, ET-1 inhibits ENaC open probability, or fraction of time that the channel is in the open conformation, in collecting ducts from control mice, but not from collecting duct nitric oxide synthase 1 knockout mice [42 && ]. These studies suggest that high Na þ intake leads to increased renal medullary osmolality and increased tubular flow; excess Na þ is sensed by ENaC channels leading to increased ET-1 production and elevated nitric oxide, which most likely inhibits ENaC and promotes excretion of excess Na þ .
Several in-vitro studies implicate ET B R in the inhibition of Na þ and water reabsorption throughout the nephron, whereas inhibition of ET A R typically has no effects [43] . However, the use of several collecting duct-specific knockout models showed that knockout of ET-1 production by the collecting duct causes salt sensitive hypertension [44] . Knockout of ET B R produced hypertension, but not to the extent of ET-1 knockout, whereas collecting duct ET A R knockout mice had no blood pressure phenotype. Interestingly, dual collecting duct ET A R/ET B R knockout mice had a similar blood pressure phenotype as collecting duct ET-1 knockout, indicating that ET A R are necessary for normal tubular function, but their absence can be compensated by a functional ET B R [45] (Fig. 3) . These are important findings because human trials of chronic kidney disease demonstrated that ET A R-specific inhibitors increased fluid retention in the treatment group [46] ; unfortunately, the high doses of antagonist used in these trials could possibly be a result of nonspecific inhibition of ET B R. However, another study recently demonstrated that the fluid retention associated with systemic ET A R inhibitors is mediated at the level of the nephron, because whole nephron ET A R knockout mice have significantly less fluid retention in response to ET A R antagonism than controls [47] . If ET B R compensates for loss of ET A R, further studies are needed to determine if dual ET A /ET B nephron knockout mice have fluid retention during chronic treatment with ET A R antagonists.
Two recent clinical trials studying the effects of ET A R inhibition on diabetic nephropathy have been undertaken with the idea that using lower doses of an ET A selective antagonist compared with previous clinical trials would extend benefit with less incidence of fluid retention. The recently completed phase 2 trial, 'Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with Atrasentan (RADAR)' showed that patients given 0.75 mg of atrasentan had significantly lower 24 h blood pressure and albuminuria with a similar number of adverse events as the placebo group.
On the other hand, volunteers given 1.25 mg had similar reductions in pressure and albuminuria as the 0.75 mg group, but had a significant rise in adverse events, suggesting that lower doses of atrasentan are optimal to provide renal protection with less incidence of fluid retention in diabetic patients [48] . Recently, an exciting phase 3 trial, 'Study of Diabetic Nephropathy with Atrasentan (SONAR)' was designed [49] . Using the optimal dose of 0.75 mg of atrasentan, the Study of Diabetic Nephropathy with Atrasentan trial will enroll over 4000 volunteers with the primary endpoint being time to doubling of serum creatinine or end-stage renal disease. This study will certainly provide the most comprehensive, well controlled study for the chronic use of ET A R antagonist in renal disease.
SEXUAL DIMORPHISM IN THE RENAL ENDOTHELIN SYSTEM
Sex differences in cardiovascular and kidney diseases are widely reported for premenopausal women, and ET-1 is a potential mediator of this sexual dimorphism. Male-female differences in the actions of ET-1 in the kidney were reviewed before [50] ; accordingly, our review here will focus on recent aspects of sexual dimorphism in the renal ET-1 system and the potential regulatory effects of sex steroids on this signaling system. Sex-related differences in endothelin receptor expression and function are a potential contributor to male-female differences in renal medullary ET-1 system signaling. Our group demonstrated increased ET A R expression in male IMCDs compared with female [51] , thus, enhanced ET A R function in male rats could limit ET B R-dependent natriuresis (Fig. 3) . Additionally, females are protected from the decrease in medullary blood flow observed in males in response to intramedullary infusion of ET-1 [52] . Moreover, Nakano et al. demonstrated that renal medullary ET A R contribute to Na þ excretion in ET B R-deficient female rats. Inner medullary ET B R expression did not appear to be sex-dependent [50] in these studies; however, others showed that ET B Rs play a significantly greater beneficial role in protecting female rats against angiotensin II-induced hypertension [53] .
Few studies have investigated the regulatory role of sex hormones on the renal ET-1 system. Estradiol suppresses renal ET-1 overproduction and the consequent renal damage in ischemia-reperfusion AKI [54] . Additionally, progesterone appears to regulate the renal ET-1 system. Zhang et al. [55] showed that pregnancy and progesterone treatment in ovariectomized mice enhance ET A R expression. Recent studies support the role of renal ET-1 in the pathophysiology of preeclampsia [56, 57] . Investigating the connection between progesterone and ET A R in preeclampsia may lead to preventive interventions for this condition.
On the other hand, the possibility that testosterone modulates the renal ET-1 system is also postulated, but available data are insufficient to draw a clear picture. Androgens may upregulate ET-1 production directly or interfere with the renin-angiotensin system, thus promoting renal damage by causing renal vasoconstriction and mitogenesis that can contribute to kidney fibrosis [58 & ]. These detrimental changes associated with renal ET-1 overexpression were attenuated by orchiectomy, suggesting an interaction of male sex hormones with the ET-1 system [59] . Collectively, male and female sex hormones are likely to be modulating the renal ET-1 system; however, more studies are needed to understand their impact on vascular and tubular components of the ET-1 system in the kidney.
Based on the detrimental effects linked to the activation of ET A Rs in the kidney, antagonism of this receptor has emerged as an attractive option for treatment of chronic kidney disease [60 && ,61]. Studies analyzing the protective effects of endothelin receptor blockers specifically in the female population are very rare. Jokar et al. [62] evaluated the effect of bosentan (dual ET A R and ET B R antagonist) on cisplatin-induced nephrotoxicity in male and female rats. The renoprotective effect of bosentan was not observed in either sex in this setting; however, it promoted the severity of renal injuries only in females [62] . This observation may be related to the blockade of ET B R, which exerts a central renoprotective role in females. A recent study suggests that endothelin receptor antagonists have estrogenlike vasculoprotective effects in ovariectomized rats. Thus, endothelin receptor antagonists may be an alternative therapy to prevent vascular disease in postmenopausal women [63] . Further research on the protective mechanisms of endothelin receptor antagonists after menopause and future clinical studies are needed.
CONCLUSION
The reviewed studies demonstrate and clarify new mechanisms involved in the role of ET-1 in renal dysfunction, and that the use of different kinds of endothelin receptor antagonism appears to be a valid therapeutic approach to prevent or attenuate the development or progression of renal disease.
